FDA Blogs

03|13|26

FDA Warning & Untitled Letters: What Pharma Marketers Need To Know 

The FDA’s recent untitled letters signal heightened scrutiny of promotional practices. Download the POV to learn what pharma marketers need to know, and how to proactively mitigate risk while staying compliant.

10|02|25

Unpacking the FDA’s Double Standard

In her latest op-ed for MM+M, Susan Perlbachs, Chief Creative Officer, delivers a powerful reflection on the FDA’s recent wave of untitled and warning letters—and the broader implications for how pharma is scrutinized compared to other industries. Read more.